实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准

张 剑, 沈维娜, 季冬梅, 王磊苹, 龚成成, 胡夕春

  1. 1. 复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032 ;
    2. 上海市抗癌协会肿瘤药物临床研究专业委员会,上海 200032
  • 出版日期:2021-04-30 发布日期:2021-04-28
  • 通讯作者: 胡夕春 E-mail: xchu2009@hotmail.com

摘要/Abstract

摘要: 药物所致间质性肺病(drug-induced interstitial lung disease,DILD)受到越来越多的关注,尤其是针对靶向药物和新一代抗体药物偶联物(antibody-drug conjugate,ADC)。DILD是一种常见的肺毒性疾病,对患者往往有致命性,因此需要早发现、早干预。无症状或无特异性症状使DILD诊断困难,故应在临床实践中定期进行CT检查。在DILD的早期采用“实体瘤中靶向药所致间质性肺病管理的复旦大学附属肿瘤医院标准”治疗,有望逆转这种药物相关的毒性及不良预后。

关键词: 靶向药所致间质性肺病管理, 实体瘤, 复旦大学附属肿瘤医院标准

Abstract: Drug-induced interstitial lung disease (DILD) has already been paid more and more attention, especially for targeted agents and newer generation antibody-drug conjugates (ADC). DILD is a common pulmonary toxicity and may be lethal to the patients, requiring early diagnosis and intervention. No symptom or no specific symptoms make the diagnosis difficult, and periodic CT monitoring should be performed in the clinical practice. Early use of Fudan University Shanghai Cancer Center criteria for management of targeted drug-induced interstitial lung disease in solid tumors can reverse the poor prognosis of this drug-related toxicity.

Key words: The management of targeted drug-induced interstitial lung disease, Solid tumors, Fudan University Shanghai Cancer Center criteria

相关文章

[1] 郑小翠,汪希鹏 . 单细胞测序技术在实体瘤研究中的应用进展[J]. 中国癌症杂志, 2019, 29(7): 535-539.